These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15389665)

  • 21. The effects of grid design on the performance of 3D-printed dry powder inhalers.
    Ye Y; Ma Y; Fan Z; Zhu J
    Int J Pharm; 2022 Nov; 627():122230. PubMed ID: 36162608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly reproducible powder aerosolisation for lung delivery using powder-specific electromechanical vibration.
    Crowder TM
    Expert Opin Drug Deliv; 2005 May; 2(3):579-85. PubMed ID: 16296776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dry powder inhalers for pulmonary drug delivery.
    Frijlink HW; De Boer AH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dry powder inhaler device influence on carrier particle performance.
    Donovan MJ; Kim SH; Raman V; Smyth HD
    J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Active and intelligent inhaler device development.
    Tobyn M; Staniforth JN; Morton D; Harmer Q; Newton ME
    Int J Pharm; 2004 Jun; 277(1-2):31-7. PubMed ID: 15158967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative analysis and design of a spray aerosol inhaler. Part 1: effects of dilution air inlets and flow paths.
    Longest PW; Hindle M
    J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):271-83. PubMed ID: 19466904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deposition and fine particle production during dynamic flow in a dry powder inhaler: a CFD approach.
    Milenkovic J; Alexopoulos AH; Kiparissides C
    Int J Pharm; 2014 Jan; 461(1-2):129-36. PubMed ID: 24296048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems.
    Wong W; Fletcher DF; Traini D; Chan HK; Crapper J; Young PM
    J Pharm Sci; 2011 Nov; 100(11):4710-21. PubMed ID: 21695695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can patients use all dry powder inhalers equally well?
    Gustafsson P; Taylor A; Zanen P; Chrystyn H
    Int J Clin Pract Suppl; 2005 Dec; (149):13-8. PubMed ID: 16279998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Need for a comparative performance standard for dry powder inhalers.
    Richards R; Saunders M
    Thorax; 1993 Nov; 48(11):1186-7. PubMed ID: 8296270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the motion of hard-shell capsules in dry powder inhalers.
    Benque B; Khinast JG
    Int J Pharm; 2019 Aug; 567():118481. PubMed ID: 31260784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates.
    Feddah MR; Brown KF; Gipps EM; Davies NM
    J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro and particle image velocimetry studies of dry powder inhalers.
    Dos Reis LG; Chaugule V; Fletcher DF; Young PM; Traini D; Soria J
    Int J Pharm; 2021 Jan; 592():119966. PubMed ID: 33161040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device.
    Fyrnys B; Stang N; Wolf-Heuss E
    Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S7-11. PubMed ID: 11385814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dry-powder inhalers: evaluation of testing methodology and effect of inhaler design.
    Broadhead J; Rouan SK; Rhodes CT
    Pharm Acta Helv; 1995 Jul; 70(2):125-31. PubMed ID: 7651970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, development and performance of a novel multidose dry-powder inhaler.
    Parry-Billings M; Boyes RN; Clisby LM; Braithwaite P; Williams S; Harper AE
    Med Device Technol; 1999 Nov; 10(9):24-8, 30, 32-4. PubMed ID: 10724653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Technological and practical challenges of dry powder inhalers and formulations.
    Hoppentocht M; Hagedoorn P; Frijlink HW; de Boer AH
    Adv Drug Deliv Rev; 2014 Aug; 75():18-31. PubMed ID: 24735675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling.
    Eliraz A; Ramirez-Rivera A; Ferranti P; Holzer R; García JM; Turcotte C; Rapatz G; Pfister P; Overend T; Kottakis J
    Int J Clin Pract; 2001 Apr; 55(3):164-70. PubMed ID: 11351769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards the optimisation and adaptation of dry powder inhalers.
    Cui Y; Schmalfuß S; Zellnitz S; Sommerfeld M; Urbanetz N
    Int J Pharm; 2014 Aug; 470(1-2):120-32. PubMed ID: 24792975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of computational approaches in inhaler development.
    Wong W; Fletcher DF; Traini D; Chan HK; Young PM
    Adv Drug Deliv Rev; 2012 Mar; 64(4):312-22. PubMed ID: 22063020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.